There are separate treatment pathways for individuals with a category A and class B CPS and for individuals with a category C CPS. In addition, the authors provide an algorithmic approach to these brokers inside the transplant inhabitants, concentrating on first line utilization of glucagon-like peptide one (GLP-one) agonists https://glp-1-medications27036.pages10.com/glp-1-tirzepatide-an-overview-72085894